Expression And Prognosis Value Of SHP2 In Patients With Pancreatic Ductal Adenocarcinoma

Objective:The purpose of this study was to test the prognostic significance and associated expression of SHP2 in patients with pancreatic ductal adenocarcinoma(PDAC).Methods:1.Consecutive sections of paraffin-embedded tissues were collected from 79 patients with pancreatic ductal adenocarcinoma who were diagnosed at Fuzhou General Hospital between January 2005 and December 2014.2.Immunohistochemistry was performed to assess the expression of SHP2 in cancer and corresponding adjacent non-cancerous tissues from 79 patients with PDAC.3.SPSS 18.0 was used to analyze all data.Survival was calculated by the Kaplan-Meier method,and differences between each group were calculated with the log-rank test.The associations between SHP2 expression and clinicopathologic features were analyzed by Pearson's chi-square(?2)test,Fisher's exact test,and Spearman's rank.Univariate and multivariate Cox regression analyses were used to identify correlations between the immunohistochemical data for SHP2 expression and clinicopathologic features in pancreatic ductal adenocarcinoma.Statistical significance was defined as P<0.05.Results:1.Immunohistochemistry revealed significantly higher rates of high SHP2 expression in PDAC tissues(55.7 %)versus adjacent non-cancer tissues(10.1 %)(P<0.05).2.Expression of SHP2 was only significantly related to histological differentiation(P=0.014)and vital status(P= 0.004).3.Patients with high SHP2 expression had shorter overall survival times compared to those with low SHP2 expression(P = 0.000).Multivariate Cox regression analysis demonstrated that SHP2 overexpression was an independent prognostic factor in PDAC(P= 0.012).Conclusions:Our study searched SHP2 expression level in PDAC for the first time and further analyzed the relationship between SHP2 with eleven clinicopathological features.The results demonstrated that ‘high SHP2 expression' was significantly higher in PDAC tissues than adjacent non-cancerous tissues and also SHP2 was an independent prognostic factor in patients with pancreatic ductal adenocarcinoma.It suggested that SHP2 might be involved in the progression of pancreatic ductal adenocarcinoma and SHP2 may be a potential prognostic marker and target for therapy.